Brand selection requires balancing cost, device comfort, GI side-effects, and a patients ability to store and use injectables safely.[11] For payers and policymakers , it means: There is an opportunity to reduce the cardiometabolic disease burden in India by using medicines that address glucose, weight, and heart risk together
L- : , , .
Pechnov O, Zicha J, Kojsov S, Dobesov Z, Jendekov L, Kunes J
doi: 10.3390/cells11030568 21 MorGCardenasI
The study authors said they hope their findings prompt regulatory agencies and drug manufacturers to update warning labels for the medication and include gastroparesis as a potential side effect
Applications and treatment As a result, dermatologists may see these patients in their offices more often than before as the weight loss market continues to boom in a way that Tolkachjov states will not decrease. In fact, some dermatologists are even prescribing these weight loss drugs themselves for dermatologic conditions an approach that is not unfounded